Skip to main content

Table 4 Clinical characteristics and echocardiographic variables of patients with or without cardiovascular event

From: Reduced fractional shortening of right ventricular outflow tract is associated with adverse outcomes in patients with left ventricular dysfunction

Parameters (-) (n = 43) Cardiovascular event  
(+) (n = 38) p value
Age 58 ± 17 66 ± 15 0.037 1)
Male 36 28 0.289 2)
NYHA functional class III-IV 6 12 0.067 2)
IHD 10 10 0.800 2)
Rhythm (Af / pacing) 10 17 0.059 2)
BNP (pg/mL) 580 ± 805 965 ± 903 0.005 3)
Total bilirubin (mg/dL) 0.93 ± 0.53 1.34 ± 0.98 0.018 1)
Uric acid (mg/dL) 7.08 ± 1.89 7.76 ± 3.18 0.235 1)
eGFR (mL/min/1.73 m2) 55.8 ± 18.9 44.9 ± 19.8 0.015 1)
Hemoglobin (g/dL) 14.3 ± 2.3 13.5 ± 1.9 0.081 1)
C-reactive protein (mg/dL) 1.4 ± 3.0 1.5 ± 2.9 0.039 3)
LAD (cm) 3.89 ± 0.66 4.43 ± 0.91 0.003 1)
IVSTd (cm) 1.08 ± 0.35 0.87 ± 0.24 0.004 1)
LVPWTd (cm) 1.11 ± 0.27 1.01 ± 0.21 0.070 1)
LVDd (cm) 6.06 ± 0.79 6.22 ± 1.25 0.465 1)
LVDs (cm) 5.28 ± 0.85 5.50 ± 1.28 0.356 1)
LVEF (%) 31.4 ± 7.6 28.5 ± 7.8 0.093 1)
RVOT-FS 0.38 ± 0.20 0.27 ± 0.17 0.008 1)
RVFAC (%) 38 ± 14 32 ± 14 0.086 1)
TR-PG (mmHg) 25 ± 14 25 ± 9 0.978 1)
Beta-blocker 25 29 0.102 2)
ACE-I/ARB 28 30 0.219 2)
Calcium channel blocker 11 6 0.413 2)
Diuretic 24 36 <0.0001 2)
Aldosterone antagonist 21 25 0.177 2)
  1. Values are expressed as absolute number or the mean ± SD. Each variable was analyzed by 1) unpaired t-test, 2) Fisher's exact test and 3) Mann-Whitney test.
  2. NYHA New York Heart Association, IHD ischemic heart disease, Af atrial fibrillation, BNP brain natriuretic peptide, eGFR estimated glomerular filtration rate, LA left atrial dimension (diastole), IVSTd intraventricular septal wall thickness (diastole), LVPWTd left ventricular posterior wall thickness (diastole), LVDd left ventricular end-diastolic dimension, LVDs left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, RVFAC right ventricular fractional area change, TR-PG tricuspid regurgitation-pressure gradient, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II type 1 receptor antagonist.